Current Report Filing (8-k)
August 11 2022 - 07:10AM
Edgar (US Regulatory)
0001760542false00017605422022-08-112022-08-11
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): August 11, 2022
HOOKIPA PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-38869
|
|
81-5395687
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
350 Fifth Avenue, 72nd
Floor, Suite
7240
|
|
|
New York, New
York
|
|
10118
|
(Address of principal executive offices)
|
|
(zip code)
|
Registrant’s telephone number, including area code: +43 1 890 63
60
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
Common stock, $0.0001
|
|
HOOK
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act. ☒
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2022, HOOKIPA Pharma Inc. (the
“Company”) announced Financial Results for the Second Quarter 2022.
A copy of the press release is being furnished as Exhibit 99.1
to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and
shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
HOOKIPA Pharma Inc.
|
Date: August 11, 2022
|
By:
|
/s/ Joern Aldag
|
|
|
Joern Aldag
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Feb 2023 to Mar 2023
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2022 to Mar 2023